Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy

Haejin In, Olga Kantor, Susan M. Sharpe, Marshall S. Baker, Mark S. Talamonti, Mitchell C. Posner

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Background: The benefit of adjuvant therapy following resection of early stage, node-negative gastric adenocarcinoma following a margin negative (R0) resection is unclear. Methods: The National Cancer Data Base was used to identify patients with a T2N0 gastric adenocarcinoma (tumor invasion into the muscularis propria) who underwent R0 resection. Patients treated with neoadjuvant therapy and those for whom lymph node count was unavailable were excluded from the analysis. Kaplan–Meier and Cox regression were used to evaluate differences in and predictors of overall survival.Results: A total of 1687 patients underwent R0 resection for T2N0 gastric adenocarcinoma between 2003–2011. Adjuvant chemotherapy treatment was administered to 7.1 and 14.1 % received adjuvant chemoradiation; 65.4 % had 0.74). Conclusions: Adequate lymph node dissection and pathologic staging is critical in directing optimal treatment of patients with early gastric cancer. Understaging as a result of suboptimal lymphadenectomy may explain the perceived benefit of adjuvant chemoradiation after an R0 resection for T2N0 gastric cancer.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalAnnals of Surgical Oncology
StateAccepted/In press - Jan 11 2016

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy'. Together they form a unique fingerprint.

Cite this